Impact of a Cancer-Associated Mutation on Poly(ADP-ribose) Polymerase1 Inhibition

Neel Shanmugam,Shubham Chatterjee,G. Andres Cisneros

DOI: https://doi.org/10.1101/2024.11.13.623412

2024-11-15

Abstract:Poly(ADP-ribose) polymerase1 (PARP1) plays a vital role in DNA repair and its inhibition in cancer cells may cause cell apoptosis. In this study, we investigated the effects of a PARP1 variant, V762A, which is strongly associated with several cancers in humans, on the inhibition of PARP1 by three FDA approved inhibitors: niraparib, rucaparib and talazoparib. Our work suggests that these inhibitors bind to the V762A mutant more effectively than to the wild-type (WT), with similar binding free energies between them. Talazoparib inhibition uniquely lowers the average residue fluctuations in the mutant than the WT including lower fluctuations of mutants N- and C-terminal residues, conserved H-Y-E traid residues and donor loop (D-loop) residues which important for catalysis more effectively than other inhibitions. However, talazoparib also enhances destabilizing interactions between the mutation site in the HD domain in the mutant than WT. Further, talazoparib inhibition significantly disrupts the functional fluctuations of terminal regions in the mutant, which are otherwise present in the WT. Lastly, the mutation and inhibition do not significantly affect PARP1s essential dynamics.

Biophysics

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the impact of a PARP1 mutation (V762A) related to cancer on the inhibition of PARP1 activity by three PARP1 inhibitors (niraparib, rucaparib and talazoparib) approved by the FDA. Specifically, the study aims to answer the following questions:

1. **Impact of the mutation on inhibitor binding**: Will the V762A mutation affect the binding affinity of these inhibitors to PARP1? If so, how exactly is it changed?

2. **Impact of the mutation on protein structure stability**: Will the V762A mutation cause changes in the PARP1 structure, especially in the stability of its key regions (such as the N - terminus, C - terminus, HD domain, etc.)?

3. **Impact of the mutation on catalytic function**: Will the V762A mutation affect the catalytic function of PARP1, especially in the presence of different inhibitors?

4. **Impact of the mutation on the mechanism of action of inhibitors**: Will the V762A mutation change the mechanism of action of these inhibitors, for example, will it enhance or weaken the "PARP trapping" effect of a specific inhibitor?

Through molecular dynamics simulations and multiple analysis methods (such as RMSD, RMSF, PCA, DCC, energy decomposition analysis, etc.), the authors studied in detail the differences in the behavior of PARP1 under the action of different inhibitors before and after the mutation. The research results show that the V762A mutation does have a significant impact on the structural stability of PARP1 and inhibitor binding, especially under the action of talazoparib, where the mutation leads to more obvious structural changes and functional fluctuations.

In summary, the core issue of this study is to evaluate how the V762A mutation affects the effectiveness and mechanism of action of PARP1 inhibitors, thereby providing a theoretical basis for the development of more effective anti - cancer drugs.